1,627 reports of this reaction
1.9% of all RIBOCICLIB reports
#10 most reported adverse reaction
METASTASES TO BONE is the #10 most commonly reported adverse reaction for RIBOCICLIB, manufactured by Novartis Pharmaceuticals Corporation. There are 1,627 FDA adverse event reports linking RIBOCICLIB to METASTASES TO BONE. This represents approximately 1.9% of all 86,238 adverse event reports for this drug.
RIBOCICLIB has an overall safety score of 85 out of 100. Patients taking RIBOCICLIB who experience metastases to bone should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
METASTASES TO BONE is a less commonly reported adverse event for RIBOCICLIB, but still significant enough to appear in the safety profile.
In addition to metastases to bone, the following adverse reactions have been reported for RIBOCICLIB:
The following drugs have also been linked to metastases to bone in FDA adverse event reports:
METASTASES TO BONE has been reported as an adverse event in 1,627 FDA reports for RIBOCICLIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
METASTASES TO BONE accounts for approximately 1.9% of all adverse event reports for RIBOCICLIB, making it a notable side effect.
If you experience metastases to bone while taking RIBOCICLIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.